CIRCULATION OF HUMAN HEMATOPOIETIC-CELLS IN SEVERE COMBINED IMMUNODEFICIENT MICE AFTER CL(2)MDP-LIPOSOME-MEDIATED MACROPHAGE DEPLETION
CIRCULATION OF HUMAN HEMATOPOIETIC-CELLS IN SEVERE COMBINED IMMUNODEFICIENT MICE AFTER CL(2)MDP-LIPOSOME-MEDIATED MACROPHAGE DEPLETION
复制标题
DOI：
10.1182/blood.v86.1.183.bloodjournal861183
复制
发表时间：
1995-07-01
期刊：
影响因子：
20.3
通讯作者：
KRAAL, G
中科院分区：
文献类型：
--
作者：
FRASER, CC;CHEN, BP;KRAAL, G
静脉注射二氯亚甲基二膦酸盐（Cl（2）MDP）脂质体可特异性清除正常小鼠脾和肝中的巨噬细胞。严重联合免疫缺陷（SCID）小鼠经Cl（2）MDP脂质体治疗后，再注射人外周血白细胞，通过荧光激活细胞分选（FAGS）分析确定，对照SCID小鼠在72小时内没有可检测到的人细胞。然而，Cl（2）MDP-脂质体处理的动物在外周血和脾脏中维持了大比例（%）的人细胞至少12天。预先植入人胎胸腺和肝脏的Cl（2）MDP-脂质体注射的SCID小鼠显示外周血中人细胞含量的短暂增加，以及脾白色髓特异性人细胞的积累，这些结果表明，小鼠单核吞噬细胞可能在清除静脉注射或SCID小鼠内源性产生的人细胞中起重要作用，2）MDP-脂质体介导的巨噬细胞耗竭允许人造血细胞在SCID小鼠中循环和存活，从而扩大了在体内研究人细胞过程的潜力。(C)1995年，美国血液学会。
Intravenous injection of dichloromethylene diphosphonate (Cl(2)MDP) encapsulated in liposomes results in specific elimination of macrophages in the spleen and liver of normal mice,Severe combined immunodeficient (SCID) mice were treated with Cl(2)MDP-liposomes followed by injection of human peripheral blood leukocytes, Control SCID mice had no detectable human cells within 72 hours as determined by fluorescence-activated cell sorting (FAGS) analysis. However, Cl(2)MDP-liposome-treated animals maintained a large proportion (%) of human cells in peripheral blood and spleen for at least 12 days. Cl(2)MDP-liposome-injected SCID mice that had previously been implanted with human fetal thymus and liver showed a transient increase in human cell content in peripheral blood, and an accumulation of human cells specific to the white pulp of the spleen, These results indicate that murine mononuclear phagocytic cells may play an important role in the clearance of human cells injected intravenously or generated endogenously in SCID mice and that Cl(2)MDP-liposome-mediated macrophage depletion allows human hematopoietic cells to circulate and survive in SCID mice, thereby expanding the potential for studying human cellular processes in vivo. (C) 1995 by The American Society of Hematology.